{
  "trial_id": "NCT00522665",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histological or cytological proof of colon or rectal adenocarcinoma",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Measurable site of disease according to RECIST that has not been previously irradiated",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Must have metastatic colorectal cancer which progressed after first line chemotherapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "+/- bevacizumab",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Blood sample collected within 21 days prior to being registered for protocol therapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "for UTG1A1 genotype analysis",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Age \u2265 18 years at the time of consent",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Written informed consent and HIPAA authorization for release of personal health information",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Females of childbearing potential and males must be willing to use an effective method of contraception",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "No more than one prior chemotherapy regimen for metastatic colorectal cancer, at least 28 days prior to being registered for protocol therapy",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "No prior treatment with cetuximab",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "No prior treatment with an mTOR inhibitor",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "No known hypersensitivity to cetuximab, RAD001 (everolimus), other rapamycins (sirolimus, temsirolimus) or to its excipients",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "No treatment with any investigational agent within 28 days prior to being registered for protocol therapy",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of acute urinary retention and is a candidate for urethral catheterization and TURP. Further evaluation revealed post-void residual: 71 mL, prostate volume (TRUS): 63 mL, PSA level: 3.5 ng/mL.",
  "_meta": {
    "topic_id": "60",
    "trial_id": "NCT00522665",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}